We dived deep into the rapidly evolving landscape of second-line and beyond treatment options for multiple myeloma. In this episode, we were joined by esteemed experts Beth Faiman, PhD, CNP, Vincent Rajkumar, MD, and Rafael Fonseca, MD, who shared their insights on the latest advancements in bispecific antibodies, CAR-T therapies, and immunomodulatory agents.

Discover the current treatment algorithms for relapsed multiple myeloma, including the role of triplet therapies, the significance of the MajesTEC-3 and MajesTEC-9 studies, and the clinical implications of new data. The discussion also covered the importance of managing side effects, the necessity of collaboration between community oncologists and academic centers, and the future of treatment in this dynamic field.

Whether you're a healthcare professional or someone interested in the latest in cancer treatment, this episode provides valuable insights into the future of multiple myeloma therapy.

Topics Covered:

Current treatment options for relapsed multiple myeloma
Insights from the MajesTEC-3 and MajesTEC-9 studies
The role of bispecific antibodies and CAR-T therapies
Managing side effects and patient care strategies
The importance of community and academic partnerships

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

X/Twitter: https://twitter.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Tune in now and stay informed about the latest in oncology!

#MultipleMyeloma, #BispecificAntibody, #CARTtherapy, #CELMoDs, #OncologyBrothers

Evolving Landscape of Multiple Myeloma: Bispecific Antibodies, CAR-T, CELMoDs

Oncology Brothers: Practice-Changing Cancer Discussions

Evolving Landscape of Multiple Myeloma: Bispecific Antibodies, CAR-T, CELMoDs